[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Investigation
November 2016

Preclinical Assessment of Young Blood Plasma for Alzheimer Disease

Author Affiliations
  • 1Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California
  • 2Department of Anatomy, University of California, San Francisco
  • 3The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California
  • 4Department of Neurosciences, University of California San Diego, La Jolla
  • 5Department of Pathology, University of California San Diego, La Jolla
  • 6Center for Tissue Regeneration, Repair and Restoration, Veterans Affairs Palo Alto Health Care System, Palo Alto, California
JAMA Neurol. 2016;73(11):1325-1333. doi:10.1001/jamaneurol.2016.3185
Key Points

Question  What is the effect of young blood factors on Alzheimer-like disease in mice?

Findings  A mouse model of Alzheimer disease was exposed to young blood either through surgically facilitated shared blood circulation or intravenous plasma administration, which was associated with a partial restoration of molecular and behavioral disease-related deficits.

Meaning  Young blood plasma benefits mice that model Alzheimer disease and could be a new therapy for humans.


Importance  Alzheimer disease (AD) pathology starts long before clinical symptoms manifest, and there is no therapy to treat, delay, or prevent the disease. A shared blood circulation between 2 mice (aka parabiosis) or repeated injections of young blood plasma (plasma from 2- to 3-month-old mice) into old mice has revealed benefits of young plasma on synaptic function and behavior. However, to our knowledge, the potential benefit of young blood has not been tested in preclinical models of neurodegeneration or AD.

Objectives  To determine whether young blood plasma ameliorates pathology and cognition in a mouse model for AD and could be a possible future treatment for the disease.

Design, Setting, and Participants  In this preclinical study, mice that harbor a human mutant APP gene, which causes familial AD, were aged to develop AD-like disease including accumulation of amyloid plaques, loss of synaptic and neuronal proteins, and behavioral deficits. The initial parabiosis studies were done in 2010, and the final studies were conducted in 2014. Alzheimer disease model mice were then treated either by surgically connecting them with a young healthy mouse, thus providing a shared blood circulation through parabiosis, or through repeated injections of plasma from young mice.

Main Outcomes and Measures  Neuropathological parameters and changes in hippocampal gene expression in response to the treatment were assessed. In addition, cognition was tested in AD model mice intravenously injected with young blood plasma.

Results  Aged mutant amyloid precursor protein mice with established disease showed a near complete restoration in levels of synaptic and neuronal proteins after exposure to young blood in parabiosis (synaptophysin P = .02; calbindin P = .02) or following intravenous plasma administration (synaptophysin P < .001; calbindin P = .14). Amyloid plaques were not affected, but the beneficial effects in neurons in the hippocampus were accompanied by a reversal of abnormal extracellular receptor kinase signaling (P = .05), a kinase implicated in AD. Moreover, young plasma administration was associated with improved working memory (P = .01) and associative memory (P = .02) in amyloid precursor protein mice.

Conclusions and Relevance  Factors in young blood have the potential to ameliorate disease in a model of AD.